Shares of Agios Pharmaceuticals (NASDAQ:AGIO) have earned an average rating of “Buy” from the fourteen research firms that are currently covering the firm, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $89.00.
Several equities research analysts recently issued reports on AGIO shares. Oppenheimer set a $83.00 price objective on shares of Agios Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, December 26th. BidaskClub raised shares of Agios Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, December 27th. ValuEngine raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, December 31st. Zacks Investment Research raised shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating and set a $68.00 target price for the company in a research report on Tuesday, January 9th. Finally, Royal Bank of Canada boosted their target price on shares of Agios Pharmaceuticals to $91.00 and gave the stock an “outperform” rating in a research report on Thursday, January 18th. They noted that the move was a valuation call.
In other news, insider Christopher Bowden sold 2,000 shares of the business’s stock in a transaction dated Thursday, April 12th. The shares were sold at an average price of $85.10, for a total transaction of $170,200.00. Following the transaction, the insider now owns 2,881 shares in the company, valued at approximately $245,173.10. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Scott Biller sold 3,000 shares of the business’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $76.04, for a total transaction of $228,120.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 88,472 shares of company stock valued at $7,077,813. Company insiders own 5.43% of the company’s stock.
Shares of AGIO stock traded up $2.09 on Wednesday, hitting $86.14. The company’s stock had a trading volume of 57,231 shares, compared to its average volume of 570,631. Agios Pharmaceuticals has a fifty-two week low of $45.11 and a fifty-two week high of $89.33. The firm has a market cap of $4,930.78, a PE ratio of -12.75 and a beta of 1.98.
Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Wednesday, February 14th. The biopharmaceutical company reported ($1.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.65) by ($0.16). Agios Pharmaceuticals had a negative net margin of 731.60% and a negative return on equity of 76.67%. The business had revenue of $9.80 million during the quarter, compared to analyst estimates of $12.65 million. During the same period in the previous year, the firm posted ($1.34) EPS. The firm’s revenue for the quarter was down 56.7% on a year-over-year basis. sell-side analysts anticipate that Agios Pharmaceuticals will post -6.25 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This report was originally published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://stocknewstimes.com/2018/04/25/agios-pharmaceuticals-agio-receives-consensus-recommendation-of-buy-from-analysts.html.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.